Exploring the health impacts of obesity and metabolic factors across different ethnic groups
Adiposity, Cardiometabolic and Neurocognitive Health Among Ethnic Groups: a Feasibility and Pilot Study (ACNH Study)
This study is trying to see how obesity and related health factors affect different ethnic groups to better understand their health risks.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 10 (estimated) |
| Ages | 18 Years to 55 Years |
| Sex | All |
| Sponsor | King's College Hospital NHS Trust Academic / other |
| Locations | 2 sites (London, United Kingdom of Great Britain and Northern Ireland and 1 other locations) |
| Trial ID | NCT06435611 on ClinicalTrials.gov |
What this trial studies
This pilot study aims to assess the feasibility of conducting a cross-sectional analysis of adiposity and its associated cardiometabolic and neurocognitive risk factors among various ethnic groups at King's College Hospital. Participants will undergo a single visit where their anthropometric measurements, liver fat levels, and cardiometabolic profiles will be evaluated. Additionally, they will complete questionnaires regarding their lifestyle, socio-economic status, and cognitive health. The study seeks to understand how these factors vary by ethnicity and to test the feasibility of cognitive assessments in diverse populations.
Who should consider this trial
Good fit: Ideal candidates for this study are men and women aged 18 years and older with a body mass index (BMI) of 30 kg/m2 or higher.
Not a fit: Patients with severe obesity (BMI > 50 kg/m2), active chronic hepatic diseases, or those currently using specific weight-loss medications may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into tailored health interventions for obesity and related conditions across different ethnic groups.
How similar studies have performed: While this approach is exploratory, similar studies have shown promise in understanding the relationship between obesity and health outcomes across diverse populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Men and women aged ≥18 years old * Body mass index (BMI) ≥ 30 kg/m2 Exclusion Criteria: * Severe obesity (BMI \> 50 kg/m2) * Pregnancy (positive urine hCG) or a recent pregnancy (in the past 6 months) * Known active chronic hepatic diseases * Known diagnosis of human immunodeficiency virus * Pre-established diagnosis of advanced renal failure (estimated Glomerular Filtration Rate (eGFR) \<30 ml/min) * Diagnosis of decompensated heart failure * History of bariatric surgery * Uncontrolled thyroid disease * Current use of the following medication: steroids (oral or injections only), weight-loss medication including over-the-counter products, glucagon-like peptide 1 (GLP-1) agonists , Sodium-Glucose Transport Protein 2 (SGLT2) Inhibitors
Where this trial is running
London, United Kingdom of Great Britain and Northern Ireland and 1 other locations
- King's College Hospital NHS Foundation Trust — London, United Kingdom of Great Britain and Northern Ireland, United Kingdom (Active_not_recruiting)
- King's College Hospital NHS Foundation Trust — London, United Kingdom (Recruiting)
Study contacts
- Principal investigator: Georgios K. Dimitriadis, PhD — Kings College Hospital
- Study coordinator: Fannie Lajeunesse-Trempe, MD, Msc
- Email: fanny.lajeunesse-trempe.1@ulaval.ca
- Phone: 14384901454
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.